The undoubted advantages of genotyping with cfDNA are now recognized by international guidelines and regulatory agencies, in particular, the FDA approved the blood-based detection of EGFR mutations in NSCLC to identify eligible patients for tyrosine kinase inhibitors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.